AustralieFrV1, PubMed, Curation, bibRecord, 001946

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.

Identifieur interne : 001946 ( PubMed/Curation ); précédent : 001945; suivant : 001947

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.

Auteurs : Svetlana A. Didichenko ; Alexei V. Navdaev ; Alexandre M O. Cukier ; Andreas Gille ; Patrick Schuetz ; Martin O. Spycher ; Patrice Thérond ; M John Chapman ; Anatol Kontush ; Samuel D. Wright [Oman]

Source :

Circulation research [ 1524-4571 ] ; 2016.

RBID : pubmed:27436846

Descripteurs français

KwdFr :
- Animaux, Anti-inflammatoires (administration et posologie), Anti-inflammatoires (métabolisme), Antioxydants (administration et posologie), Antioxydants (métabolisme), Cholestérol (métabolisme), Humains, Lignée cellulaire, Lipoprotéines HDL (administration et posologie), Lipoprotéines HDL (métabolisme), Perfusions veineuses, Souris, Souris de lignée C57BL, Souris knockout, Stress oxydatif (), Stress oxydatif (physiologie).
MESH :
- administration et posologie : Anti-inflammatoires, Antioxydants, Lipoprotéines HDL.
- métabolisme : Anti-inflammatoires, Antioxydants, Cholestérol, Lipoprotéines HDL.
- physiologie : Stress oxydatif.
- Animaux, Humains, Lignée cellulaire, Perfusions veineuses, Souris, Souris de lignée C57BL, Souris knockout, Stress oxydatif.

English descriptors

KwdEn :
- Animals, Anti-Inflammatory Agents (administration & dosage), Anti-Inflammatory Agents (metabolism), Antioxidants (administration & dosage), Antioxidants (metabolism), Cell Line, Cholesterol (metabolism), Humans, Infusions, Intravenous, Lipoproteins, HDL (administration & dosage), Lipoproteins, HDL (metabolism), Mice, Mice, Inbred C57BL, Mice, Knockout, Oxidative Stress (drug effects), Oxidative Stress (physiology).
MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Antioxidants, Lipoproteins, HDL.
- chemical , metabolism : Anti-Inflammatory Agents, Antioxidants, Cholesterol, Lipoproteins, HDL.
- drug effects : Oxidative Stress.
- physiology : Oxidative Stress.
- Animals, Cell Line, Humans, Infusions, Intravenous, Mice, Mice, Inbred C57BL, Mice, Knockout.

Abstract

CSL112, human apolipoprotein A-I (apoA-I) reconstituted with phosphatidylcholine, is known to cause a dramatic rise in small high-density lipoprotein (HDL).

DOI: 10.1161/CIRCRESAHA.116.308685
PubMed: 27436846

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001970

Links to Exploration step

pubmed:27436846

Curation

No country items

Svetlana A. Didichenko

<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>

Alexei V. Navdaev

<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>

Alexandre M O. Cukier

<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>

Andreas Gille

<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>

Patrick Schuetz

<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>

Martin O. Spycher

<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>

Patrice Thérond

<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>

M John Chapman

<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>

Anatol Kontush

<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.</title>
<author><name sortKey="Didichenko, Svetlana A" sort="Didichenko, Svetlana A" uniqKey="Didichenko S" first="Svetlana A" last="Didichenko">Svetlana A. Didichenko</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Navdaev, Alexei V" sort="Navdaev, Alexei V" uniqKey="Navdaev A" first="Alexei V" last="Navdaev">Alexei V. Navdaev</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Cukier, Alexandre M O" sort="Cukier, Alexandre M O" uniqKey="Cukier A" first="Alexandre M O" last="Cukier">Alexandre M O. Cukier</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gille, Andreas" sort="Gille, Andreas" uniqKey="Gille A" first="Andreas" last="Gille">Andreas Gille</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Schuetz, Patrick" sort="Schuetz, Patrick" uniqKey="Schuetz P" first="Patrick" last="Schuetz">Patrick Schuetz</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Spycher, Martin O" sort="Spycher, Martin O" uniqKey="Spycher M" first="Martin O" last="Spycher">Martin O. Spycher</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Therond, Patrice" sort="Therond, Patrice" uniqKey="Therond P" first="Patrice" last="Thérond">Patrice Thérond</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Chapman, M John" sort="Chapman, M John" uniqKey="Chapman M" first="M John" last="Chapman">M John Chapman</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kontush, Anatol" sort="Kontush, Anatol" uniqKey="Kontush A" first="Anatol" last="Kontush">Anatol Kontush</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Wright, Samuel D" sort="Wright, Samuel D" uniqKey="Wright S" first="Samuel D" last="Wright">Samuel D. Wright</name>
<affiliation wicri:level="1"><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.). samuel.wright@cslbehring.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27436846</idno>
<idno type="pmid">27436846</idno>
<idno type="doi">10.1161/CIRCRESAHA.116.308685</idno>
<idno type="wicri:Area/PubMed/Corpus">001970</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001970</idno>
<idno type="wicri:Area/PubMed/Curation">001946</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001946</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.</title>
<author><name sortKey="Didichenko, Svetlana A" sort="Didichenko, Svetlana A" uniqKey="Didichenko S" first="Svetlana A" last="Didichenko">Svetlana A. Didichenko</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Navdaev, Alexei V" sort="Navdaev, Alexei V" uniqKey="Navdaev A" first="Alexei V" last="Navdaev">Alexei V. Navdaev</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Cukier, Alexandre M O" sort="Cukier, Alexandre M O" uniqKey="Cukier A" first="Alexandre M O" last="Cukier">Alexandre M O. Cukier</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gille, Andreas" sort="Gille, Andreas" uniqKey="Gille A" first="Andreas" last="Gille">Andreas Gille</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Schuetz, Patrick" sort="Schuetz, Patrick" uniqKey="Schuetz P" first="Patrick" last="Schuetz">Patrick Schuetz</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Spycher, Martin O" sort="Spycher, Martin O" uniqKey="Spycher M" first="Martin O" last="Spycher">Martin O. Spycher</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Therond, Patrice" sort="Therond, Patrice" uniqKey="Therond P" first="Patrice" last="Thérond">Patrice Thérond</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Chapman, M John" sort="Chapman, M John" uniqKey="Chapman M" first="M John" last="Chapman">M John Chapman</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kontush, Anatol" sort="Kontush, Anatol" uniqKey="Kontush A" first="Anatol" last="Kontush">Anatol Kontush</name>
<affiliation><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</nlm:affiliation>
<wicri:noCountry code="subField">PA (S.D.W.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Wright, Samuel D" sort="Wright, Samuel D" uniqKey="Wright S" first="Samuel D" last="Wright">Samuel D. Wright</name>
<affiliation wicri:level="1"><nlm:affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.). samuel.wright@cslbehring.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
</affiliation>
</author>
</analytic>
<series><title level="j">Circulation research</title>
<idno type="eISSN">1524-4571</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Anti-Inflammatory Agents (administration & dosage)</term>
<term>Anti-Inflammatory Agents (metabolism)</term>
<term>Antioxidants (administration & dosage)</term>
<term>Antioxidants (metabolism)</term>
<term>Cell Line</term>
<term>Cholesterol (metabolism)</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Lipoproteins, HDL (administration & dosage)</term>
<term>Lipoproteins, HDL (metabolism)</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Mice, Knockout</term>
<term>Oxidative Stress (drug effects)</term>
<term>Oxidative Stress (physiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anti-inflammatoires (administration et posologie)</term>
<term>Anti-inflammatoires (métabolisme)</term>
<term>Antioxydants (administration et posologie)</term>
<term>Antioxydants (métabolisme)</term>
<term>Cholestérol (métabolisme)</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Lipoprotéines HDL (administration et posologie)</term>
<term>Lipoprotéines HDL (métabolisme)</term>
<term>Perfusions veineuses</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
<term>Souris knockout</term>
<term>Stress oxydatif ()</term>
<term>Stress oxydatif (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents</term>
<term>Antioxidants</term>
<term>Lipoproteins, HDL</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Anti-Inflammatory Agents</term>
<term>Antioxidants</term>
<term>Cholesterol</term>
<term>Lipoproteins, HDL</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-inflammatoires</term>
<term>Antioxydants</term>
<term>Lipoprotéines HDL</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Oxidative Stress</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Anti-inflammatoires</term>
<term>Antioxydants</term>
<term>Cholestérol</term>
<term>Lipoprotéines HDL</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Stress oxydatif</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Oxidative Stress</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Mice, Knockout</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Perfusions veineuses</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
<term>Souris knockout</term>
<term>Stress oxydatif</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">CSL112, human apolipoprotein A-I (apoA-I) reconstituted with phosphatidylcholine, is known to cause a dramatic rise in small high-density lipoprotein (HDL).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27436846</PMID>
<DateCreated><Year>2016</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>05</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>05</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4571</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>119</Volume>
<Issue>6</Issue>
<PubDate><Year>2016</Year>
<Month>Sep</Month>
<Day>02</Day>
</PubDate>
</JournalIssue>
<Title>Circulation research</Title>
<ISOAbbreviation>Circ. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.</ArticleTitle>
<Pagination><MedlinePgn>751-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCRESAHA.116.308685</ELocationID>
<Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">CSL112, human apolipoprotein A-I (apoA-I) reconstituted with phosphatidylcholine, is known to cause a dramatic rise in small high-density lipoprotein (HDL).</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore the mechanisms by which the formation of small HDL particles is induced by CSL112.</AbstractText>
<AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Infusion of CSL112 into humans caused elevation of 2 small diameter HDL fractions and 1 large diameter fraction. Ex vivo studies showed that this remodeling does not depend on lipid transfer proteins or lipases. Rather, interaction of CSL112 with purified HDL spontaneously gave rise to 3 HDL species: a large, spherical species composed of apoA-I from native HDL and CSL112; a small, disc-shaped species composed of apoA-I from CSL112, but smaller because of the loss of phospholipids; and the smallest species, lipid-poor apoA-I composed of apoA-I from HDL and CSL112. Time-course studies suggest that remodeling occurs by an initial fusion of CSL112 with HDL and subsequent fission leading to the smaller forms. Functional studies showed that ATP-binding cassette transporter 1-dependent cholesterol efflux and anti-inflammatory effects in whole blood were carried by the 2 small species with little activity in the large species. In contrast, the ability to inactivate lipid hydroperoxides in oxidized low-density lipoprotein was carried predominantly by the 2 largest species and was low in lipid-poor apoA-I.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We have described a mechanism for the formation of small, highly functional HDL species involving spontaneous fusion of discoidal HDL with spherical HDL and subsequent fission. Similar remodeling is likely to occur during the life cycle of apoA-I in vivo.</AbstractText>
<CopyrightInformation>© 2016 The Authors.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Didichenko</LastName>
<ForeName>Svetlana A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo><Affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Navdaev</LastName>
<ForeName>Alexei V</ForeName>
<Initials>AV</Initials>
<AffiliationInfo><Affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cukier</LastName>
<ForeName>Alexandre M O</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gille</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schuetz</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Spycher</LastName>
<ForeName>Martin O</ForeName>
<Initials>MO</Initials>
<AffiliationInfo><Affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thérond</LastName>
<ForeName>Patrice</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chapman</LastName>
<ForeName>M John</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo><Affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kontush</LastName>
<ForeName>Anatol</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wright</LastName>
<ForeName>Samuel D</ForeName>
<Initials>SD</Initials>
<AffiliationInfo><Affiliation>From the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.). samuel.wright@cslbehring.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>07</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Circ Res</MedlineTA>
<NlmUniqueID>0047103</NlmUniqueID>
<ISSNLinking>0009-7330</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C584257">CSL112</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber>
<NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2014 Jul 14;35(27):1792-800</RefSource>
<PMID Version="1">24639426</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2016 Jan;36(1):156-65</RefSource>
<PMID Version="1">26543096</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 1986 Mar;27(3):236-50</RefSource>
<PMID Version="1">3016129</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Opin Lipidol. 2010 Aug;21(4):312-8</RefSource>
<PMID Version="1">20581677</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Med Chem. 2009;16(6):667-75</RefSource>
<PMID Version="1">19199930</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2012 Apr 9;209(4):807-17</RefSource>
<PMID Version="1">22473958</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Pharmacol. 2014 Mar;54(3):301-10</RefSource>
<PMID Version="1">24122814</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 1985 May 17;834(3):285-300</RefSource>
<PMID Version="1">3995066</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Dec 18;371(25):2383-93</RefSource>
<PMID Version="1">25404125</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2014 Feb;15(2):152-60</RefSource>
<PMID Version="1">24317040</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 1993 Sep 8;1169(3):291-300</RefSource>
<PMID Version="1">7548123</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2011 Jan;52(1):175-84</RefSource>
<PMID Version="1">20978167</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1881-8</RefSource>
<PMID Version="1">12920049</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2169-75</RefSource>
<PMID Version="1">19762782</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Jan 13;364(2):127-35</RefSource>
<PMID Version="1">21226578</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 1978 Jan 30;80(2):405-12</RefSource>
<PMID Version="1">414755</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 1991 Jan;32(1):97-106</RefSource>
<PMID Version="1">1901346</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2006 May 11;441(7090):173-8</RefSource>
<PMID Version="1">16688168</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochem J. 2001 Dec 1;360(Pt 2):379-85</RefSource>
<PMID Version="1">11716766</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2005 Oct;46(10):2246-53</RefSource>
<PMID Version="1">16061948</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2001 Jul 20;276(29):26898-905</RefSource>
<PMID Version="1">11325961</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Subcell Biochem. 2010;51:183-227</RefSource>
<PMID Version="1">20213545</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2015 Oct;56(10 ):2002-9</RefSource>
<PMID Version="1">26254308</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 1995 Jan 6;270(1):189-96</RefSource>
<PMID Version="1">7814372</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2015 Mar 27;116(7):1133-42</RefSource>
<PMID Version="1">25589556</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 1995 Sep;15(9):1419-23</RefSource>
<PMID Version="1">7670957</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Chem. 2011 Mar;57(3):392-410</RefSource>
<PMID Version="1">21266551</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2005 May;46(5):896-903</RefSource>
<PMID Version="1">15687350</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Clin Pract Cardiovasc Med. 2006 Mar;3(3):144-53</RefSource>
<PMID Version="1">16505860</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2003 Mar;44(3):645-50</RefSource>
<PMID Version="1">12562853</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Diabetes Endocrinol. 2015 Jul;3(7):507-13</RefSource>
<PMID Version="1">26025389</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2106-14</RefSource>
<PMID Version="1">24969776</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1977 Aug;74(8):3340-4</RefSource>
<PMID Version="1">269394</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801</RefSource>
<PMID Version="1">20075420</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2015 Feb;15(2):104-16</RefSource>
<PMID Version="1">25614320</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2003 Jun 20;278(25):22530-6</RefSource>
<PMID Version="1">12690114</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2011 Aug 15;187(4):1529-35</RefSource>
<PMID Version="1">21810617</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1910-6</RefSource>
<PMID Version="1">25060793</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2202-11</RefSource>
<PMID Version="1">23868939</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC5006797</OtherID>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">antioxidant</Keyword>
<Keyword MajorTopicYN="Y">apolipoprotein A-I</Keyword>
<Keyword MajorTopicYN="Y">cholesterol</Keyword>
<Keyword MajorTopicYN="Y">high-density lipoproteins</Keyword>
<Keyword MajorTopicYN="Y">inflammation</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>03</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>07</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>7</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>7</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>5</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27436846</ArticleId>
<ArticleId IdType="pii">CIRCRESAHA.116.308685</ArticleId>
<ArticleId IdType="doi">10.1161/CIRCRESAHA.116.308685</ArticleId>
<ArticleId IdType="pmc">PMC5006797</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001946 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001946 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:27436846
   |texte=   Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:27436846" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Curation

No country items

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki